Cargando…

SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies

SARS-CoV-2 breakthrough infections, associated with waning immunity, increase systemic antibody levels. In this study, we analyzed the impact of the infection timing on the magnitude of the systemic humoral response and whether breakthrough infections also boost antibody levels in the salivary compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Badano, María Noel, Pereson, Matias J., Sabbione, Florencia, Keitelman, Irene, Aloisi, Natalia, Chuit, Roberto, de Bracco, María M. E., Fink, Susana, Baré, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054801/
https://www.ncbi.nlm.nih.gov/pubmed/36992118
http://dx.doi.org/10.3390/vaccines11030534
_version_ 1785015759117746176
author Badano, María Noel
Pereson, Matias J.
Sabbione, Florencia
Keitelman, Irene
Aloisi, Natalia
Chuit, Roberto
de Bracco, María M. E.
Fink, Susana
Baré, Patricia
author_facet Badano, María Noel
Pereson, Matias J.
Sabbione, Florencia
Keitelman, Irene
Aloisi, Natalia
Chuit, Roberto
de Bracco, María M. E.
Fink, Susana
Baré, Patricia
author_sort Badano, María Noel
collection PubMed
description SARS-CoV-2 breakthrough infections, associated with waning immunity, increase systemic antibody levels. In this study, we analyzed the impact of the infection timing on the magnitude of the systemic humoral response and whether breakthrough infections also boost antibody levels in the salivary compartment. We observed that the combination of infection plus vaccination, regardless of infection timing, produced a sharp increase in systemic antibodies, which were higher in subjects infected after third doses. Moreover, despite high systemic antibody levels, breakthrough infections after dose three occurred and boosted antibody levels in the salivary compartment. These results suggest that current vaccination strategies against COVID-19 should be improved. Results also showed that determination of salivary antibodies against SARS-CoV-2 could be a valuable tool in disease prevalence studies, for the follow-up of vaccinated individuals, and to assist vaccination strategies against COVID-19, especially in settings where blood sampling cannot be fulfilled.
format Online
Article
Text
id pubmed-10054801
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100548012023-03-30 SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies Badano, María Noel Pereson, Matias J. Sabbione, Florencia Keitelman, Irene Aloisi, Natalia Chuit, Roberto de Bracco, María M. E. Fink, Susana Baré, Patricia Vaccines (Basel) Brief Report SARS-CoV-2 breakthrough infections, associated with waning immunity, increase systemic antibody levels. In this study, we analyzed the impact of the infection timing on the magnitude of the systemic humoral response and whether breakthrough infections also boost antibody levels in the salivary compartment. We observed that the combination of infection plus vaccination, regardless of infection timing, produced a sharp increase in systemic antibodies, which were higher in subjects infected after third doses. Moreover, despite high systemic antibody levels, breakthrough infections after dose three occurred and boosted antibody levels in the salivary compartment. These results suggest that current vaccination strategies against COVID-19 should be improved. Results also showed that determination of salivary antibodies against SARS-CoV-2 could be a valuable tool in disease prevalence studies, for the follow-up of vaccinated individuals, and to assist vaccination strategies against COVID-19, especially in settings where blood sampling cannot be fulfilled. MDPI 2023-02-24 /pmc/articles/PMC10054801/ /pubmed/36992118 http://dx.doi.org/10.3390/vaccines11030534 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Badano, María Noel
Pereson, Matias J.
Sabbione, Florencia
Keitelman, Irene
Aloisi, Natalia
Chuit, Roberto
de Bracco, María M. E.
Fink, Susana
Baré, Patricia
SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title_full SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title_fullStr SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title_full_unstemmed SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title_short SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
title_sort sars-cov-2 breakthrough infections after third doses boost igg specific salivary and blood antibodies
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054801/
https://www.ncbi.nlm.nih.gov/pubmed/36992118
http://dx.doi.org/10.3390/vaccines11030534
work_keys_str_mv AT badanomarianoel sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT peresonmatiasj sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT sabbioneflorencia sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT keitelmanirene sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT aloisinatalia sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT chuitroberto sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT debraccomariame sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT finksusana sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies
AT barepatricia sarscov2breakthroughinfectionsafterthirddosesboostiggspecificsalivaryandbloodantibodies